NasdaqGM - Nasdaq Real Time Price USD

Veracyte, Inc. (VCYT)

29.71

-0.79

(-2.59%)

At close: 4:00:00 PM EDT

29.71

0.00

(0.00%)

After hours: 4:05:12 PM EDT

Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer

SOUTH SAN FRANCISCO, Calif., April 25, 2025--Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer

Business Wire 6 days ago

VCYT
-2.59%
Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting

SOUTH SAN FRANCISCO, Calif., April 22, 2025--Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing Will Be Presented at AUA Annual Meeting

Business Wire 9 days ago

VCYT
-2.59%
Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute’s SEER Specialized Database Release

SOUTH SAN FRANCISCO, Calif., April 21, 2025--Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to National Cancer Institute’s SEER Specialized Database Release

Business Wire 10 days ago

VCYT
-2.59%
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.

A revolution in oncology could help the 18 million cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences.

Investor's Business Daily 13 days ago

EXAS

GH

NTRA
+0.28%
Should You Continue to Hold Veracyte Stock in Your Portfolio?

Strength in the Afirma and Decipher franchises continues to bode well for VCYT stock.

Zacks 14 days ago

VCYT
-2.59%

BSX
Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025

SOUTH SAN FRANCISCO, Calif., April 16, 2025--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the first quarter of 2025 after the close of market on Wednesday, May 7, 2025. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.

Business Wire 14 days ago

VCYT
-2.59%
Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks 16 days ago

VCYT
-2.59%
Here's Why Veracyte (VCYT) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks 17 days ago

VCYT
-2.59%
Bruker Debuts Fourier 80 Multinuclear Benchtop FT-NMR: Stock to Gain?

BRKR's latest innovation offers 1H NMR and a choice of 15 X-nuclei with just one click.

Zacks 20 days ago

BRKR

VCYT
-2.59%
Veracyte And 2 More Stocks That Might Be Trading Below Their Estimated Value

Amid recent market volatility, with major indices like the Dow Jones and Nasdaq experiencing significant declines, investors are increasingly on the lookout for stocks that may be trading below their intrinsic value. In such turbulent times, identifying undervalued stocks can offer potential opportunities as these equities might not fully reflect their companies' fundamental strengths or future prospects.

Simply Wall St. 21 days ago

BSY

CCCS

VCYT
-2.59%
Veracyte (VCYT) Just Overtook the 20-Day Moving Average

Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?

Zacks 21 days ago

VCYT
-2.59%
Strength Seen in Veracyte (VCYT): Can Its 13.0% Jump Turn into More Strength?

Veracyte (VCYT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks 21 days ago

VCYT
-2.59%

GKOS
Here's How Much You'd Have If You Invested $1000 in Veracyte a Decade Ago

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

Zacks 21 days ago

VCYT
-2.59%
Veracyte (VCYT) Introduces AI-Powered Cancer Detection – Faster and More Accurate Than Ever!

We recently published a list of 9 AI News and Ratings on Investors’ Radar. In this article, we are going to take a look at where Veracyte, Inc. (NASDAQ:VCYT) stands against other AI news and ratings on investors’ radar. According to a Reuters report posted on March 25, Chinese AI firms have made significant progress […]

Insider Monkey last month

VCYT
-2.59%
Veracyte (VCYT) Up 0.7% Since Last Earnings Report: Can It Continue?

Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks last month

VCYT
-2.59%

PEN
Wall Street Analysts Believe Veracyte (VCYT) Could Rally 35.05%: Here's is How to Trade

The mean of analysts' price targets for Veracyte (VCYT) points to a 35.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks last month

VCYT
-2.59%
New Data Demonstrate Accuracy of Veracyte’s Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer

SOUTH SAN FRANCISCO, Calif., March 25, 2025--New Data Demonstrate Accuracy of Veracyte’s Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer.

Business Wire last month

VCYT
-2.59%
US High Growth Tech Stocks With Promising Potential

The United States market has shown a positive trend, rising 1.8% over the last week and 10% over the past year, with earnings projected to grow by 14% annually. In this environment, identifying high growth tech stocks involves looking for companies that not only capitalize on current technological advancements but also demonstrate strong potential for sustained revenue and profit growth in alignment with these market conditions.

Simply Wall St. last month

KRYS

VCYT
-2.59%

BTDR
GMED Stock Jumps 41.8% in a Year: What's Behind the Rally?

Globus Medical's robust musculoskeletal offerings and synergies from the NuVasive merger are fueling its stock gains.

Zacks last month

GMED

VCYT
-2.59%

BSX
Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25

SOUTH SAN FRANCISCO, Calif., March 19, 2025--Veracyte Announces 8 Abstracts Highlighting Performance and Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25

Business Wire last month

VCYT
-2.59%

Performance Overview

Return	VCYT	S&P 500 (^GSPC)
YTD	-24.97%	-4.72%
1-Year	+47.59%	+11.67%
3-Year	+45.14%	+35.63%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Veracyte, Inc. (VCYT)

Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer

Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting

Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute’s SEER Specialized Database Release

The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.

Should You Continue to Hold Veracyte Stock in Your Portfolio?

Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025

Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term

Here's Why Veracyte (VCYT) is a Strong Growth Stock

Bruker Debuts Fourier 80 Multinuclear Benchtop FT-NMR: Stock to Gain?

Veracyte And 2 More Stocks That Might Be Trading Below Their Estimated Value

Veracyte (VCYT) Just Overtook the 20-Day Moving Average

Strength Seen in Veracyte (VCYT): Can Its 13.0% Jump Turn into More Strength?

Here's How Much You'd Have If You Invested $1000 in Veracyte a Decade Ago

Veracyte (VCYT) Introduces AI-Powered Cancer Detection – Faster and More Accurate Than Ever!

Veracyte (VCYT) Up 0.7% Since Last Earnings Report: Can It Continue?

Wall Street Analysts Believe Veracyte (VCYT) Could Rally 35.05%: Here's is How to Trade

New Data Demonstrate Accuracy of Veracyte’s Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer

US High Growth Tech Stocks With Promising Potential

GMED Stock Jumps 41.8% in a Year: What's Behind the Rally?

Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25

Performance Overview